Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > The Good and the Bad
View:
Post by Bradwait on Mar 03, 2021 7:13am

The Good and the Bad

Some will see this pp before results as an indication results are not good. However its not likely the company knows the results until this Friday. So therefore the pp is prudent and not large considering the massive upside potential here.

There are other examples of repurposed drugs that have gone on to be blockbusters in their new indications. Most of you know blockbuster refers to a drug with sales in excess of $1 Billion annually. So next to this type of upside a $2.7 million raise from just over 10 million shares is not a big deal at all. Don't forget we also raised a few million recently with the exercise of outstanding warrants . The company has some cash and that is not a negative.

From Aug.12, 2020 news release:

the Company is betting that this quiet and unassuming safe generic drug may soon become a global blockbuster. The Company is claiming it has filed new patents globally for Ifenprodil for the treatment of respiratory diseases. Algernon has advised that they are following the same re-purposed drug business model as Biogen with their re-purposed drug Tecfidera and Celgene’s Thalidomide, both billion dollar blockbuster drugs in their own right.

I googled Tecfidera and found they did over $1 billion in sales from a single quarter. Yes in just 3 months thats what a repurposed drug did in sales.

Hello is anyone awake out there? We are in the largest medical crisis of our lifetimes and here this little penny stock may well have a repurposed drug that kicks butt where it needs to be kicked. If so, this has blockbuster written all over it. Massive upside potential from this tiny cap we are starting with.

We will know a lot more next week. Don't forget the two videos regarding the phase 2 trial which both sound extremely positive.

Comment by futuregains on Mar 03, 2021 7:30am
We are here Brad. Some of us have been around since last winter. Some longer than that. Still holding but have little faith in this management group. Just holding my breath and waiting to see. I truly hope you are right. Here's to Ifenprodil's success. 
Comment by GObabyGO1 on Mar 03, 2021 7:57am
Wow! So shady...The CSO leaves and now more smoke and mirrors just before results are expected? Are these guys for real? This is not going to end well
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities